Angiogenesis Status in Patients with Acute Myeloid Leukemia: From Diagnosis to Post-hematopoietic Stem Cell Transplantation

Overview

Journal Int J Organ Transplant Med

Date 2017 Aug 23

PMID 28828165

Citations 6

Authors

M Mohammadi Najafabadi

K Shamsasenjan

P Akbarzadehalaleh

Affiliations

Soon will be listed here.

Abstract

As already proven in solid tumors, increased angiogenesis leads to increased number of blood vessels, resulting in unfavorable outcomes and resistance to chemotherapy. It was previously thought that angiogenesis plays no role in the pathogenesis of acute myeloid leukemia (AML), due to the fact that AML is a liquid tumor. However, many studies have suggested that increased angiogenesis has important roles in patients with AML, including increased numbers of vessels in bone marrow and pro-angiogenic factors, as well as decreased anti-angiogenic factors. Also a large number of studies demonstrated that a two-way communication is established between leukemic and endothelial cells, as a component of the vessel wall, in the bone marrow of patients with AML. These two cells support the survival and proliferation of each other through a paracrine pathway, resulting in resistance to chemotherapy. In addition, It is well-established that increased angiogenesis is associated with unfavorable prognosis, lower survival rate, resistance to chemotherapy, and relapse. Furthermore, increased angiogenesis affects the response to treatment, hematopoietic stem cell transplantation (HSCT) outcome and graft versus host disease (GVHD) occurrence. In this regard, this review will address vascular endothelial growth factor (VEGF) and angiopoietin (Ang), two of the most important angiogenic factors, in patients with AML before and after HSCT. By increasing our understanding of the role of endothelial cells and angiogenic factors in patients with AML from diagnosis to post-HSCT, new therapeutic strategies can be developed to reduce angiogenesis, improve patients' survival and reduce complications.

Citing Articles

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways.

Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M Cell Commun Signal. 2023; 21(1):252.

PMID: 37735675 PMC: 10512514. DOI: 10.1186/s12964-023-01282-2.

BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia.

Lacina P, Butrym A, Turlej E, Stachowicz-Suhs M, Wietrzyk J, Mazur G J Clin Med. 2022; 11(2).

PMID: 35054026 PMC: 8779396. DOI: 10.3390/jcm11020332.

Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success.

Michelozzi I, Kirtsios E, Giustacchini A Cancers (Basel). 2021; 13(11).

PMID: 34198742 PMC: 8201025. DOI: 10.3390/cancers13112816.

Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML.

Modarres P, Mohamadi Farsani F, Nekouie A, Vallian S Sci Rep. 2021; 11(1):12485.

PMID: 34127725 PMC: 8203646. DOI: 10.1038/s41598-021-91864-2.

Anti-angiogenic activity of ShengMaBieJia decoction and in acute myeloid leukaemia tumour-bearing mouse models.

Wang M, Ma B, Dai X, Zhang H, Dai H, Wang J Pharm Biol. 2020; 58(1):454-464.

PMID: 32432951 PMC: 7301716. DOI: 10.1080/13880209.2020.1764059.

References

Moiseev I, Lapin S, Surkova E, Lerner M, Vavilov V, Afanasyev B . Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(12):1677-82. DOI: 10.1016/j.bbmt.2013.08.015. View

Lunn R, Sumar N, Bansal A, Treleaven J . Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. Hematology. 2005; 10(2):107-14. DOI: 10.1080/10245330400001975. View

Litwin C, Leong K, Zapf R, Sutherland H, Naiman S, Karsan A . Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. Am J Hematol. 2002; 70(1):22-30. DOI: 10.1002/ajh.10092. View

Schmidt T, Carmeliet P . Angiogenesis: a target in solid tumors, also in leukemia?. Hematology Am Soc Hematol Educ Program. 2011; 2011:1-8. DOI: 10.1182/asheducation-2011.1.1. View

Gratwohl A, Baldomero H . Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol. 2009; 16(6):420-6. DOI: 10.1097/MOH.0b013e328330990f. View

Sanaat Z, Khalili R, Almasi S, Aliparasti M, Tavangar S, Movasaghpoor A . Does Chemotherapy Change Expression of VEGF A&C and MVD in Acute Myeloid Leukemia?. Int J Hematol Oncol Stem Cell Res. 2015; 8(3):24-9. PMC: 4305378. View

Min C, Kim S, Lee M, Eom K, Kim Y, Kim H . Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006; 38(2):149-56. DOI: 10.1038/sj.bmt.1705410. View

Kuzu I, Beksac M, Arat M, Celebi H, Elhan A, Erekul S . Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma. 2004; 45(6):1185-90. DOI: 10.1080/1042819032000159915. View

Cogle C, Bosse R, Brewer T, Migdady Y, Shirzad R, Kampen K . Acute myeloid leukemia in the vascular niche. Cancer Lett. 2015; 380(2):552-560. DOI: 10.1016/j.canlet.2015.05.007. View

10.

Kim D, Lee N, Lee M, Sohn S . Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008; 14(12):1408-16. DOI: 10.1016/j.bbmt.2008.09.022. View

11.

Patan S . Vasculogenesis and angiogenesis. Cancer Treat Res. 2004; 117:3-32. DOI: 10.1007/978-1-4419-8871-3_1. View

12.

Doan P, Chute J . The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia. 2011; 26(1):54-62. DOI: 10.1038/leu.2011.236. View

13.

Stucki A, Rivier A, Gikic M, Monai N, Schapira M, Spertini O . Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001; 97(7):2121-9. DOI: 10.1182/blood.v97.7.2121. View

14.

Casalou C, Fragoso R, Nunes J, Dias S . VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. Leukemia. 2007; 21(7):1590-4. DOI: 10.1038/sj.leu.2404668. View

15.

Appelbaum F, Gundacker H, Head D, Slovak M, Willman C, Godwin J . Age and acute myeloid leukemia. Blood. 2006; 107(9):3481-5. PMC: 1895766. DOI: 10.1182/blood-2005-09-3724. View

16.

Alitalo K, Carmeliet P . Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002; 1(3):219-27. DOI: 10.1016/s1535-6108(02)00051-x. View

17.

Chen T, Luque A, Lee S, Anderson S, Segura T, Iruela-Arispe M . Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol. 2010; 188(4):595-609. PMC: 2828913. DOI: 10.1083/jcb.200906044. View

18.

Dias S, Shmelkov S, Lam G, Rafii S . VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2002; 99(7):2532-40. DOI: 10.1182/blood.v99.7.2532. View

19.

Santos S, Dias S . Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004; 103(10):3883-9. DOI: 10.1182/blood-2003-05-1634. View

20.

Hussong J, Rodgers G, Shami P . Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 1999; 95(1):309-13. View